New Mesothelioma Test - Showing Effectiveness For Pleural Mesothelioma Patients

Mesothelioma is an asbestos related cancer caused by exposure to asbestos over a long period of time. Symptoms for mesothelioma may not become apparent for decades after the initial exposure to asbestos. Thus it is usually not detected until the late stages after serious side effects begin to present themselves.

What Are Some Of The Diagnosis Of Pleural Mesothelioma?

Mesothelioma in general is extremely difficult to diagnose since symptoms do not appear for a long time after initial asbestos exposure occurs. And in most cases pleural mesothelioma is often mistaken for influenza or pneumonia or other more common disease making it extremely difficult to diagnose and treat.

What Are The Symptoms Of Pleural Mesothelioma?

The symptoms of pleural mesothelioma are very non-specific which makes it very difficult to diagnose at an early stage and treat appropriately. Other symptoms may not appear for decades after exposure to asbestos. Some of the symptoms include:

* Abdominal swelling * Anemia * Acute pain in the abdominal region and chest area * Coughing up blood * Difficulty swallowing * Fatigue * Shortness of breath * Persistent dry cough * Weight loss

What Is This New Test?

A new gene ratio test to help predict which pleural mesothelioma patients will benefit from multiple modes of therapy and surgical procedure was developed by researchers at the Birgham and Womens Hospital in Boston, Massachusetts. This test has shown to be effective in predicting postsurgical outcome in pleural mesothelioma patient this is indeed a very important breakthrough in the diagnosis and treatment of mesothelioma. How Is This Test Used?

The gene ratio test is used to analyze relative expression levels of four genes involved in malignant mesothelioma. The researchers believed that there was a need to develop a molecular test that could predict surgical outcome due to the lack of current means of assessing prognosis in determining which mesothelioma patient will benefit from surgery of trimodality therapy.

How Effective Is This Test?

According to the researchers trimodality treatment that includes chemotherapy and radiation with surgical resection leads to longer life expectancy than nonsurgical therapy in patients with malignant pleural mesothelioma. Although this treatment is effective in longer survival rate it is only beneficial to about 50 percent of malignant pleural mesothelioma patients which means the other 50 percent of patients may not benefit from this test. Overall this test is an effective new development in determining which patient will see an improved mesothelioma prognosis.

What Is The Survival Rate Of This Test?

The survival rate for patients that received trimodality therapy is currently around one to two years. However approximately 20 percent of patients survive for three to fifteen years. This significant increase in survival is definitely good news for patients who may be more genetically apt to benefits from this aggressive new treatment approach.

Due to the positive outcome of this test, researchers are pushing for this test to become a standard practice in diagnosing and planning treatment for pleural mesothelioma patients.

How Reliable Is This Test?

According to researchers their test indicates that it can be performed on specimens obtained in a minimally invasive biopsy performed before major surgical intervention. The test also indicates that it can be used as a reliable source to help inform the clinical decision of whether to perform major surgery or trimodal therapies in addition to accurately predicting postsurgical outcome.

The new developments of drugs and treatment for pleural mesothelioma such as this give hope to those suffering from mesothelioma and their loved ones. It is with great hope that these new tests will one day be 100 percent effective in treating this disease at all stages.